September 20 2024 - Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2

Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2
Keytruda beaten by Summit’s bispecific in NSCLC
DermaSensor’s skin cancer detection device helps clinicians in published study
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings
*please scroll down for all the latest news*

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

*please scroll down for all the latest news*